Roche writes off $3B+ in pipeline assets, $750M for Spark-acquired gene therapies

Paul Schloesser

Associate Editor

Roche faces a downward turn in revenue this year, writing down or off billions in assets, and predicting a decline in revenue from Covid-19 products …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche writes off $3B+ in pipeline assets, $750M for Spark-acquired gene therapies

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Roche writes off $3B+ in pipeline as­sets, $750M for Spark-ac­quired gene ther­a­pies

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Roche writes off $3B+ in pipeline assets, $750M for Spark-acquired gene therapies